Lilly obesity combo achieves 23.3% weight loss in mid-stage trial
Eli Lilly's amylin-Zepbound combination achieved 23.3% weight loss in a mid-stage study, surpassing current treatments but showing high discontinuation rates.
Palanor Wire · composed from 3 outlets · every claim links to its sources
What happened
Eli Lilly's amylin-incretin combination, called eloraTZP, achieved weight loss of up to 23.3% in a mid-stage trial. 2 Data was presented at the European Association for the Study of Diabetes (EASD) meeting in Milan. 2 The investigational combination therapy showed significant weight loss but high discontinuation rates, raising questions about tolerability. 3 Novo demonstrated continued weight loss following a switch to an oral treatment, while AbbVie and Boehringer provided glimpses of their obesity contenders. 1
Why it matters
The 23.3% weight loss exceeds results from current obesity treatments including Wegovy, Zepbound, CagriSema and retatrutide. 23 High discontinuation rates suggest tolerability challenges that could affect the therapy's viability. 3
What to watch
Further results and tolerability data from continued development will determine whether the combination advances to later-stage trials. 3
Sources · 3
[1]STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial
STAT
[2]3 takeaways from a European obesity scientific meeting
BioPharma Dive
[3]#EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes
Endpoints News
Matched signals
Lattice signals Numen pinned to this story at publish time.
No matched signals on this story.
Unlock the analytical widgets on every article — signal matches, Trends snapshots, X overlays, agent reasoning — with a Member account.
Upgrade →On X right now
Top engagement posts about this topic, ranked by likes + retweets + quotes.
No high-engagement X posts captured for this topic. Either the topic is too quiet or the upstream API was unavailable when this article published.
Unlock the analytical widgets on every article — signal matches, Trends snapshots, X overlays, agent reasoning — with a Member account.
Upgrade →Your read
How did this article land?
Three sliders. Optional comment. Anonymous is fine.
Open to anyone. One response per reader.